New single-center retrospective outcomes for lecanemab in early Alzheimer’s disease show that about half of patients discontinued treatment before or at the 18-month mark, while the remainder transitioned to a maintenance phase. The report characterizes real-world persistence under routine care rather than trial-only conditions. The finding is likely to inform how clinicians and health systems plan dosing schedules and patient follow-up, especially where discontinuation could affect long-term disease management pathways. It also adds to ongoing evidence on how anti-amyloid therapies perform over time in practice settings, where tolerability and logistics can influence continuation.